This finding yielded a similar result to a previous study aimed to estimate the value of combined multipanel diagnostic accuracy of troponin-I, N-terminal proatrial natriuretic peptide, cystatin-C, and high-sensitivity C–reactive protein (hs-CRP) in patients with coronary artery diseases (CAD) at the time of admission, suggesting that combined assessments of two biomarkers for diagnostic performance for CAD were better than single biomarkers (Al-Mumin et al., 2020). The gene discussed is CST3; the disease is coronary artery disorder.